Dimethyl amino azetidine amides as JAK inhibitors
AssigneeTheravance Biopharma R&D IP, LLC
InventorsDaniel D. Long, Cameron Smith, Corbin Thompson
Life of this patent
Estimating the term…
Abstract
The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds and methods of using such compounds to treat respiratory diseases.
Claims20
A method of treating a respiratory disease in a mammal, the method comprising administering to the mammal a pharmaceutical composition comprising a compound of formula (I):
- wherein:
- n is 0, 1, or 2;
- R1 is C1-3 alkyl;
- and
- each R2 is independently C1-3 alkyl;
- or a pharmaceutically-acceptable salt thereof,
- and a pharmaceutically-acceptable carrier.
A method of treating lung transplant rejection in a mammal, the method comprising administering to the mammal a pharmaceutical composition comprising a compound of formula (I):
- wherein:
- n is 0, 1, or 2;
- R1 is C1-3 alkyl;
- and
- each R2 is independently C1-3 alkyl;
- or a pharmaceutically-acceptable salt thereof,
- and a pharmaceutically-acceptable carrier.
Dependencies are inferred from the claim text.